PHARMACODYNAMIC MONITORING OF CYCLOSPORINE

被引:30
作者
AWNI, WM
机构
[1] UNIV MINNESOTA,COLL PHARM,MINNEAPOLIS,MN 55455
[2] HENNEPIN CTY MED CTR,DRUG EVALUAT UNIT,MINNEAPOLIS,MN 55415
关键词
D O I
10.2165/00003088-199223060-00004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The efficacy of cyclosporin as an immunosuppressive agent is largely based on clinical indicators such as graft survival, rejection or nephrotoxicity. Therapeutic monitoring is necessary to evaluate the efficacy of cyclosporin therapy. The most widely used method for monitoring cyclosporin therapy is the measurement of predose trough blood concentrations of the drug. The relationship of a single or multiple blood cyclosporin concentration to slowly evolving outcomes is difficult to establish. Some investigators have found a good correlation between cyclosporin trough concentrations on the one hand and cyclosporin toxicity and rejection on the other, but others have not. Therapeutic monitoring of cyclosporin may be enhanced using some biological assays for immunosuppression (pharmacodynamic monitoring) in addition to cyclosporin trough concentrations (pharmacokinetic monitoring). However, direct monitoring of the immune response to cyclosporin therapy using a clinically applicable biological assay is difficult. Some pharmacodynamic parameters have been suggested as biological markers in the clinical monitoring of cyclosporin.
引用
收藏
页码:428 / 448
页数:21
相关论文
共 128 条
[1]  
AGGARWAL BB, 1984, J BIOL CHEM, V259, P686
[2]   ONSET AND DEVELOPMENT OF CYCLOSPORINE-A EFFECTS ON LYMPHOCYTES OF CARDIAC PATIENTS BEFORE HEART-TRANSPLANTATION [J].
ALBENGRES, E ;
RIANT, P ;
MOREL, M ;
HAMBERGER, C ;
TAVOLARO, O ;
LOISANCE, D ;
TILLEMENT, JP ;
CACHERA, JP .
THERAPEUTIC DRUG MONITORING, 1990, 12 (01) :2-7
[3]  
Alexander H R, 1985, Curr Surg, V42, P18
[4]  
AWNI WM, 1990, TRANSPLANT P, V22, P1343
[5]   RENAL EFFECTS OF CYCLOSPORINE [J].
BENNETT, WM .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1990, 23 (06) :1280-1287
[6]  
BLOEMENA E, 1988, CLIN EXP IMMUNOL, V71, P308
[7]  
BOREL JF, 1977, IMMUNOLOGY, V32, P1017
[8]  
BOREL JF, 1989, PHARMACOL REV, V41, P259
[9]   BIOLOGICAL EFFECTS OF CYCLOSPORIN-A - NEW ANTILYMPHOCYTIC AGENT [J].
BOREL, JF ;
FEURER, C ;
GUBLER, HU ;
STAHELIN, H .
AGENTS AND ACTIONS, 1976, 6 (04) :468-475
[10]   INCREASED FACTOR-VIII AS AN INDEX OF VASCULAR INJURY IN CYCLOSPORINE NEPHROTOXICITY [J].
BROWN, Z ;
NEILD, GH ;
WILLOUGHBY, JJ ;
SOMIA, NV ;
CAMERON, SJ .
TRANSPLANTATION, 1986, 42 (02) :150-153